[Skip to Content]
[Skip to Content Landing]
October 5, 1970

Preferential Attack on Cancer by Selected SH Inhibitors

JAMA. 1970;214(1):146. doi:10.1001/jama.1970.03180010086025

To the Editor.—  In sensitivity tests on hundreds of human cancers, selected sulfhydryl (SH) inhibitors have shown greater effect against tumors than against normal tissues. Clinically, SH inhibitors have caused the regression of a variety of human carcinomas, sarcomas, and lymphomas without injury to wound healing and with minimal injury to hematologic status and even improvement in some patients. The drug regimens are started within 24 to 48 hours of major cancer surgery, such as palliative bowel resection or pelvic exenteration. In two series totalling over 100 patients, the majority of patients whose tumors could be measured objectively received objective benefit from chemotherapy with the SH inhibitor oxophenarsine plus adjuncts, alone or in combination with other anticancer drugs which were picked in accord with sensitivity tests on each patient's own cancer.1From the work of Di Paolo2 and Kondo3 the sensitivity tests are now known to be